BNS Staff, writers and editors —

BioNews, the owner and publisher of this site, employs science writers and editors, most of whom have PhDs in the life sciences, as well as veteran journalists, who ensure stories are well-written and easy to understand. Our stories undergo a comprehensive fact-checking and editing process to confirm accuracy, objectiveness, and thoroughness in order to best serve our audience of patients and caregivers.

Articles by BioNews Staff

FDA Postmarket Trial for PAH Treatment Bosentan Reveals Drug Does Not Reduce Time To Mortality Rates

Drug maker Actelion has indicated that the company’s Food and Drug Administration (FDA)–approved pulmonary arterial hypertension (PAH) drug Bosentan, which is also known under the brand names of Actelion and Tracleer, recently failed a key FDA postmarket test. The test, which was part of the postmarket COMPASS 2 trial, revealed that Bosentan did not reduce time…

Early-Stage Pulmonary Arterial Hypertension Therapy From Pulmokine Awarded $1.5 Million Through Federally Funded VITA Contract

Rensselaer, New York-based biopharmaceutical company Pulmokine recently made a major announcement regarding the company’s efforts in developing a novel therapy for pulmonary arterial hypertension (PAH). In a press release from late March, Pulmokine indicated that that the National Heart, Lung, and Blood Institute (NHLBI), a division of the federally run National…